MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 500810 | Name: GANT58
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GANT58 is a cell-permeable tetrapyridinylthiophene compound that acts as downstream Hedgehog (Hh) pathway blocker and targets Gli-mediated gene transactivation (IC50 ~ 5 µM in SAG-stimulated Shh-L2 cells).

Chemical Structure

GANT58
GANT58
CAS#64048-12-0

Theoretical Analysis

MedKoo Cat#: 500810

Name: GANT58

CAS#: 64048-12-0

Chemical Formula: C24H16N4S

Exact Mass: 392.1096

Molecular Weight: 392.48

Elemental Analysis: C, 73.45; H, 4.11; N, 14.28; S, 8.17

Price and Availability

Size Price Availability Quantity
50mg USD 250.00 2 Weeks
100mg USD 450.00 2 Weeks
250mg USD 850.00 2 Weeks
500mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
GANT58; GANT 58; GANT-58; NSC 75503; NSC75503; NSC-75503
IUPAC/Chemical Name
2,3,4,5-Tetra(4-pyridyl)thiophene
InChi Key
USWLOKMMUTWFMD-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H16N4S/c1-9-25-10-2-17(1)21-22(18-3-11-26-12-4-18)24(20-7-15-28-16-8-20)29-23(21)19-5-13-27-14-6-19/h1-16H
SMILES Code
C1(C2=CC=NC=C2)=C(C3=CC=NC=C3)C(C4=CC=NC=C4)=C(C5=CC=NC=C5)S1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
        
Product Data
Product Data
Instruction
View handling instruction
Biological target:
GANT 58 (NSC 75503) is a potent GLI antagonist that inhibits GLI1-induced transcription with IC50 of 5 μM.
In vitro activity:
To test this, this study exposed the ESFT cell line A673 to GANT58 at doses shown to inhibit GLI1 transactivation. Figure 5D demonstrates the anticipated transcriptional downregulation of Patched, NKX2.2 and GAS1 by treatment with GANT58. Reference: PLoS One. 2009 Oct 27;4(10):e7608. https://pubmed.ncbi.nlm.nih.gov/19859563/
In vivo activity:
Substantial osteolytic lesions were observed radiographically in the mice treated only with the Empty-NPs (nanoparticles) after 4 weeks, while smaller and fewer lesions were visible in mice treated with GANT58-NP (Fig. 7B). Quantitative assessment of both lesion area and number confirmed that the osteolytic lesions in the GANT58-NP-treated mice were significantly smaller and fewer (Fig. 7C–D). Reference: J Control Release. 2019 Oct;311-312:257-272. https://pubmed.ncbi.nlm.nih.gov/31494183/
Solvent mg/mL mM comments
Solubility
DMF 2.5 6.37
DMF:PBS (pH 7.2) (1:1) 0.5 1.27
DMSO 10.1 25.59
Ethanol 10.7 27.26
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 392.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Joo J, Christensen L, Warner K, States L, Kang HG, Vo K, Lawlor ER, May WA. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS One. 2009 Oct 27;4(10):e7608. doi: 10.1371/journal.pone.0007608. PMID: 19859563; PMCID: PMC2763206. 2. Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, Matsui W, Endo Y, Rubin JS, Toretsky J, Uren A. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem. 2009 Apr 3;284(14):9074-82. doi: 10.1074/jbc.M806233200. Epub 2009 Feb 3. PMID: 19189974; PMCID: PMC2666556. 3. Vanderburgh JP, Kwakwa KA, Werfel TA, Merkel AR, Gupta MK, Johnson RW, Guelcher SA, Duvall CL, Rhoades JA. Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease. J Control Release. 2019 Oct;311-312:257-272. doi: 10.1016/j.jconrel.2019.08.038. Epub 2019 Sep 5. PMID: 31494183; PMCID: PMC7007697. 4. Chen X, Shi C, Cao H, Chen L, Hou J, Xiang Z, Hu K, Han X. The hedgehog and Wnt/β-catenin system machinery mediate myofibroblast differentiation of LR-MSCs in pulmonary fibrogenesis. Cell Death Dis. 2018 May 29;9(6):639. doi: 10.1038/s41419-018-0692-9. PMID: 29844390; PMCID: PMC5974360.
In vitro protocol:
1. Joo J, Christensen L, Warner K, States L, Kang HG, Vo K, Lawlor ER, May WA. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS One. 2009 Oct 27;4(10):e7608. doi: 10.1371/journal.pone.0007608. PMID: 19859563; PMCID: PMC2763206. 2. Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, Matsui W, Endo Y, Rubin JS, Toretsky J, Uren A. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem. 2009 Apr 3;284(14):9074-82. doi: 10.1074/jbc.M806233200. Epub 2009 Feb 3. PMID: 19189974; PMCID: PMC2666556.
In vivo protocol:
1. Vanderburgh JP, Kwakwa KA, Werfel TA, Merkel AR, Gupta MK, Johnson RW, Guelcher SA, Duvall CL, Rhoades JA. Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease. J Control Release. 2019 Oct;311-312:257-272. doi: 10.1016/j.jconrel.2019.08.038. Epub 2019 Sep 5. PMID: 31494183; PMCID: PMC7007697. 2. Chen X, Shi C, Cao H, Chen L, Hou J, Xiang Z, Hu K, Han X. The hedgehog and Wnt/β-catenin system machinery mediate myofibroblast differentiation of LR-MSCs in pulmonary fibrogenesis. Cell Death Dis. 2018 May 29;9(6):639. doi: 10.1038/s41419-018-0692-9. PMID: 29844390; PMCID: PMC5974360.